This is (supposed to be) a reflective diary by a (not very) anonymous biomedical scientist who works somewhere in the south of England. One day this diary may well be submitted to the Health and Care Professions Council as evidence of ongoing continual professional development....
Well…
I had a few minutes spare so I thought I might do a crafty BTLP-TACT exercise.
I
was presented with two cases:
93888
A
twenty-four-year-old woman on outpatients requiring group & save
She
grouped as O Rh(D) Positive with a negative antibody screen
10985
A
fifty-three-year-old woman in the haematology clinic requiring two units of
irradiated blood
She
grouped as A Rh(D) Negative with a negative antibody screen
I
selected two units of irradiated blood
I
got the green light
The results of the latest parasitology NEQAS became available today.
2202 PA1
I saw a ring form... and then what looked like a few intact parasites of P. vivax.
2202 PA2
I didn’t see any parasites
The results of the latest morphology NEQAS became available today.
2203 BF1
I saw:
Lymphocytosis (2nd
most reported)
hairy
cells (1st most reported)
smear
cells (6th most reported)
hypochromia
Thrombocytopenia (3rd
most reported)
I said this was a case of hairy cell leukaemia. It was.
2203 BF2
I saw:
Blast
cells (1st most reported)
Neutropenia (2nd
most reported)
Thrombocytopenia (3rd
most reported)
Giant
platelets
I said this was a case of ALL. It was.
I shall count this as a success
The
Fritsma
Factor newsletter appeared in my in-box this morning. Perhaps leaning a tad
more to the specialist laboratory than I might like it to, I always find this to
be a rather good source of CPD…
I was reading about TTP somewhere else recently... wish I could remember where.
The monthly Stem Cell Evidence Alert came today. I haven’t mentioned this one for a while, but one or two of the articles referring to bone marrow transplants were enlightening.
ARTICLE OF THE MONTH In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial.Marks, D.I., et al. (2022) The Lancet. Haematology. 9(4):e276-e288.PICO SUMMARY +++++ |
SELECTED ARTICLES
Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity, an EBMT IEWP study. Albert, M. H., et al. (2022) Blood [record in progress]Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01.Bonifazi, F. et al. (2022) Bone Marrow Transplantation [record in progress]Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial.Farag, S., et al. (2022) Bone Marrow Transplantation [record in progress]Neutralizing antibody and T cell responses to SARS-CoV-2 vaccination in hematopoietic cell transplant recipients.Gavriilaki, E., et al. (2022) Bone Marrow Transplantation [record in progress]Feasibility and efficacy of partially replacing post-transplant cyclophosphamide with bendamustine in pediatric and young adult patients undergoing haploidentical bone marrow transplantationKatsanis, E., et al. (2022) Transplantation and Cellular Therapy [record in progress]Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy.Khaled, S. K., et al. (2022) Journal of Clinical Oncology: Jco2102389.Busulfan, Melphalan, and Etoposide (BuMe) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High Risk Non-Hodgkin's Lymphoma: A Multicenter Randomized Phase II Study by the Consortium for Improving Survival of Lymphoma (CISL).Kim, K.H., et al. (2022) Cancer Research and Treatment [record in progress]Mesenchymal Stromal Cells for Treating Steroid-Resistant Acute and Chronic Graft Versus Host Disease: A Multicenter Compassionate Use Experience.MacÃas-Sánchez, M. D. M., et al. (2022) Stem Cell Translational Medicine [record in progress]Evaluation of the pharmacokinetic interaction between letermovir and tacrolimus in allogeneic hematopoietic cell transplant recipients.Marciano, K. A., et al. (2022) Transplantation and Cellular Therapy [record in progress]
The monthly Transfusion Evidence Alert came today. I can’t pretend to have intently studied the lot; it would take a month to do so. But a quick glance through was rather enlightening on one or two topics…
ARTICLE OF THE MONTH Tranexamic Acid in Patients Undergoing Noncardiac Surgery.Devereaux, P.J., et al. (2022). The New England Journal of Medicine.PICO Summary available +++++ |
TOP ARTICLES
Risk factors for bleeding in people living with Hemophilia A and B treated with regular prophylaxis: a systematic review of the literature.Germini, F., et al. (2022). Journal of Thrombosis and Haemostasis.
Robotically applied hemostatic clamping for care-under-fire: harnessing bomb robots for hemorrhage control.Kirkpatrick, A.W., et al. (2022). Canadian Journal of Surgery. Journal Canadien de Chirurgie.
Impact of restrictive red blood cell transfusion strategy on thrombosis-related events: A meta-analysis and systematic review.Maimaitiming, M., et al. (2022). Vox Sanguinis.
Over-the-scope-clips versus standard treatment in high-risk patients with acute non-variceal upper gastrointestinal bleeding: a randomised controlled trial (STING-2).Meier, B., et al. (2022). Gut. [Record in Progress].
Practice review: Evidence-based and effective management of anaemia in palliative care patients.Neoh, K., et al. (2022). Palliative Medicine.
Effects of Freshly Irradiated vs Irradiated and Stored Red Blood Cell Transfusion on Cerebral Oxygenation in Preterm Infants: A Randomized Clinical Trial.Saito-Benz, M., et al. (2022). JAMA Pediatrics.
The efficacy and safety of tranexamic acid in lumbar surgery: A meta-analysis of randomized-controlled trials.Xiao, K., et al. (2022). Joint Diseases and Related Surgery.
I found the latest update from Diagnostica Stago in my junk folder today. You can read it by clicking here.
I’ve often said that I struggle to get good coagulation-related CPD… I’m surprised that this newsletter isn’t better than it is… I find more and more these monthly updates focus on the esoteric stuff that are utterly irrelevant whereas what I’m looking for is a more efficient way to work, or an explanation for that which I do on a daily basis but about which I am a tad vague…
